| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Tubulin beta-4B chain;Tubulin beta-2 chain;Tubulin beta-2C chain;TUBB4B;TUBB2C; |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Gene ID | |
| Host | |
| Immunogen | A synthesized peptide derived from human TEMT |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Boster Bio Anti-TEMT Rabbit Monoclonal Antibody catalog # M09175-1. Tested in WB application. This antibody reacts with Human, Mouse, Rat.
Protein: T-cell surface glycoprotein CD3 zeta chain | Gene: Tubulin beta-4B chain | Target: INMT | Function: Tubulin is the major constituent of microtubules. It binds two moles of GTP, one at an exchangeable site on the beta chain and one at a non-exchangeable site on the alpha chain. | Research areas: Actin Assembly,Actin, etc.,Cytoskeleton,Cytoskeleton/ECM,Microfilaments,Signal Transduction
Host: Rabbit | Clonality/Clone: Monoclonal / Clone: 29I89 | Isotype: IgG | Reactivity: Human,Mouse,Rat | Immunogen: A synthesized peptide derived from human TEMT | Concentration: 0.5mg/ml | Purification: Affinity-chromatography
Applications: WB
Observed MW: 25 kDa | Calculated MW: 49831 MW
Cellular localization: Cytoplasm, cytoskeleton.
Tissue details: Ubiquitous. .
Status: Active
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
